The bacteriophage formulation TP-102 was tested in a phase I/IIa clinical trial and was well tolerated. No significant adverse events were observed, suggesting its therapeutic potential for bacterial infections in diabetic foot ulcers.

The application of phage therapy for multidrug-resistant infections is mainly limited to personalized therapy due to the narrow host range of individual phages. Here, Kim et al. identify groups of pha...